🩺 IMSPARK: medical equipment accurate and reliable for everyone🩺

 🩺 Imagine... medical equipment  accurate and reliable for everyone🩺 

💡 Imagined Endstate: 

A Pacific where pulse oximeters, devices that measure blood oxygen levels, are designed and tested to account for the diversity of skin pigmentation, race, and ethnicity in our region and where healthcare providers and patients are aware of the potential biases and limitations of these devices.

🔗Link:

Ref Here

📚Source: 

U.S. Food and Drug Administration. (2024). Performance Evaluation of Pulse Oximeters Taking into Consideration Skin Pigmentation, Race and Ethnicity.

💥 What’s the Big Deal: 

Pulse oximeters are widely used in clinical settings and at home to monitor blood oxygen levels, which can indicate severe health conditions such as COVID-19, asthma, or heart failure. 🌈However, several studies have shown that pulse oximeters can be inaccurate and unreliable for people with darker skin pigmentation because they use light to detect blood flow. This can lead to delayed diagnosis, inappropriate treatment, or missed opportunities for intervention.💉 The FDA issued guidance to improve the performance evaluation of pulse oximeters, taking into consideration skin pigmentation, race, and ethnicity. 🙌This document provides recommendations for device manufacturers, researchers, and healthcare professionals on how to design, test, and use pulse oximeters to minimize bias and ensure safety and effectiveness for all patients.

#PulseOximeters, #MedicalEquipment, #HealthEquity, #Pacific, #FDA,#IMSPARK, 

#CodedGaze

🔬IMSPARK: Advancing Alzheimer's Treatment🔬

🔬IMSPARK: Advancing Alzheimer's Treatment🔬

💡 IMAGINED ENDSTATE:

Imagine a future where individuals and families affected by Alzheimer's disease have access to effective treatments that target the underlying disease process, providing relief from symptoms and improving quality of life. Through continued research and innovation, we envision a world where Alzheimer's is better understood, and ultimately, a cure is discovered, bringing hope and healing to those affected by this devastating condition.

Link:                                            

🔗 [Link to the FDA article]

Source:

📚 FDA. (2023, January 6). FDA Grants Accelerated Approval for Alzheimer's Disease Treatment.

💥 WHAT'S THE BIG DEAL:

 The FDA grants accelerated approval for Leqembi, a breakthrough Alzheimer's disease treatment targeting the underlying disease process. It provides a new treatment option addressing amyloid beta plaque, a hallmark characteristic of the disease. This approval represents a significant advancement in Alzheimer's treatment, offering hope to millions affected. However, warnings for potential side effects like ARIA and infusion-related reactions emphasize the need for careful monitoring and management. This milestone underscores the importance of ongoing research and innovation to improve treatment options and find a cure for Alzheimer's.

 

#FDA, #Alzheimers, #Breakthrough, #Healthcare, #HealthAccess